Hauser, R.A., Shulman, L.M., Trugman, J.M., Roberts, J.W., Mori, A., Ballerini, R. and Sussman, N.M., Istradefylline 6002-US-013 Study Group (2008) Study of Istradefylline in Patients with Parkinson’s Disease on Levodopa with Motor Fluctuations. Movement Disorders, 23, 2177-2185.
https://doi.org/10.1002/mds.22095

has been cited by the following article:

• TITLE: Differences between Istradefylline Responders and Non-Responders in Parkinson’s Disease

  AUTHORS: Asako Yoritaka, Nobutaka Hattori

  KEYWORDS: Parkinson’s Disease, Istradefylline, Adenosine A2A Receptor Antagonist, Wearing-Off, Sleepiness

  JOURNAL NAME: Advances in Parkinson's Disease, Vol.6 No.2, March 31, 2017

  ABSTRACT: Background: Istradefylline is a selective adenosine A2A receptor antagonist approved for Parkinson’s disease (PD) patients with wearing-off symptoms. The Japanese phase III trial showed that 20 mg of orally administrated istradefylline decreased the Off-time. However, istradefylline showed prominent effects in some patients and no benefits in others. We examined the differences in characteristics between responders and non-responders who received 8 weeks of 20 mg/day istradefylline. Methods: Thirty-one patients were enrolled (age, 65.4 [SD 10.4] years; disease duration, 10.4 [SD 6.1] years; daily levodopa dosage, 553.2 [SD 228.7] mg; frequency of levodopa consumption, 4.7 [SD 1.5] times; levodopa equivalent dose, 811.2 [SD 307.5] mg). Results: There were significant differences (p Conclusions: Younger or female patients who are not excessively sleepy during daytime are better candidates for the istradefylline therapy.